Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (vol 45, pg 810, 2020)
- Authors
- Kroschinsky, F[Kroschinsky, Frank]; Middeke, JM[Middeke, Jan Moritz]; Janz, M[Janz, Martin]; Lenz, G[Lenz, Georg]; Witzens-Harig, M[Witzens-Harig, Mathias]; Bouabdallah, R[Bouabdallah, Reda]; La Rosee, P[La Rosee, Paul]; Viardot, A[Viardot, Andreas]; Salles, G[Salles, Gilles]; Kim, SJ[Kim, Seok Jin]; Kim, TM[Kim, Tae Min]; Ottmann, O[Ottmann, Oliver]; Chromik, J[Chromik, Joerg]; Quinson, AM[Quinson, Anne-Marie]; von Wangenheim, U[von Wangenheim, Ute]; Burkard, U[Burkard, Ute]; Berk, A[Berk, Andreas]; Schmitz, N[Schmitz, Norbert]
- Issue Date
- Feb-2021
- Publisher
- SPRINGER
- Citation
- INVESTIGATIONAL NEW DRUGS, v.39, no.1, pp.283 - 284
- Indexed
- SCIE
SCOPUS
- Journal Title
- INVESTIGATIONAL NEW DRUGS
- Volume
- 39
- Number
- 1
- Start Page
- 283
- End Page
- 284
- ISSN
- 0167-6997
- Abstract
- The article Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.